Myovant Sciences Stock Crashes On Poor Trial Data For Prostate Cancer Treatment

Myovant Sciences Stock Crashes On Poor Trial Data For Prostate Cancer Treatment

Myovant Sciences posted poor trial data for part of a Phase 3 study for a prostate cancer treatment that awaits key FDA action later this year, and MYOV stock plummeted out of a buy zone.